Literature DB >> 12213868

Abnormal bone mineral accrual in adolescent girls with anorexia nervosa.

Leslie A Soyka1, Madhusmita Misra, Aparna Frenchman, Karen K Miller, Steven Grinspoon, David A Schoenfeld, Anne Klibanski.   

Abstract

Anorexia nervosa (AN) is increasingly common in adolescent girls and occurs at a time of peak bone mass formation. Osteopenia is common in adolescent girls with AN, and in a cross-sectional study, we have reported low bone formation markers in such girls. To determine the impact of chronic undernutrition on bone mineral accrual in contrast to healthy controls, we prospectively measured bone mineral density (BMD) and body composition by dual energy x-ray absorptiometry, bone metabolism markers, and nutritional and hormonal status at baseline, 6 months, and 12 months in 19 adolescent girls with AN (mean +/- SEM, 15.4 +/- 0.4 yr) and 19 controls of comparable chronological and skeletal age. Overall, nutritional status in subjects with AN improved (mean percentage increase in body mass index from baseline, 9.2 +/- 1.9% and 15.2 +/- 2.6% at 6 and 12 months, respectively), with 11 subjects having recovered weight at 12 months. However, lumbar BMD at 12 months (AN, 0.88 +/- 0.02 g/cm(2), vs. control, 0.98 +/- 0.03 g/cm(2); P = 0.008) remained significantly reduced in AN compared with controls, even in recovered subjects. This was due to significant increases in lumbar BMD in controls vs. no change in AN subjects over the year (0.003 +/- 0.001 g/cm(2).month vs. 0.000 +/- 0.001 g/cm(2).month, respectively; P = 0.04). The most significant determinant of change in lumbar BMD at 12 months was change in lean body mass in both AN (r = 0.62; P = 0.008) and control (r = 0.80; P = 0.0006) groups. There were significant increases in surrogate markers of bone turnover in subjects with AN compared with controls as assessed by osteocalcin (AN, 0.9 +/- 0.4 micro g/liter.month, vs. control, -1.1 +/- 0.4 micro g/liter.month; P = 0.0007), bone-specific alkaline phosphatase (AN, 0.6 +/- 0.5 U/liter.month, vs. control, -1.5 +/- 0.4 U/liter.month; P = 0.002), deoxypyridinoline [AN, 0.1 +/- 0.1 nmol/mmol creatinine (cr).month, vs. control, -0.4 +/- 0.1 nmol/mmol cr.month; P = 0.005], and N-telopeptide (AN, 4 +/- 4 nmol BCE/mmol cr/month, vs. control, -9 +/- 4 nmol BCE/mmol cr/month; P = 0.01). Changes in IGF-I levels over the year were highly correlated with changes in bone turnover over the same period in AN (osteocalcin, r = 0.77; P = 0.001; deoxypyridinoline, r = 0.66; P = 0.01). A rise in N-telopeptide over the year was correlated with an increase in all bone mineral measures, including lumbar bone mineral content (r = 0.58; P = 0.03) and BMD (r = 0.53; P = 0.05) and total bone mineral content (r = 0.69; P = 0.006) and BMD (r = 0.69; P = 0.006) in the AN group. Therefore, despite recovery over 1 yr, poor bone mineral accrual persists in adolescent girls with AN in contrast to rapid bone accrual in healthy girls. Normalization of bone turnover markers occurs in association with nutritional recovery and an increase in the nutritionally dependent bone trophic factor IGF-I. A rise in bone turnover markers may be an early indicator of increase in BMD in recovering girls with AN.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213868     DOI: 10.1210/jc.2001-011889

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  91 in total

1.  Relationship between serum omentin-1 level and bone mineral density in girls with anorexia nervosa.

Authors:  L-J Guo; T-J Jiang; L Liao; H Liu; H-B He
Journal:  J Endocrinol Invest       Date:  2012-06-18       Impact factor: 4.256

2.  Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations.

Authors:  Joo-Pin Foo; Ole-Petter R Hamnvik; Christos S Mantzoros
Journal:  Metabolism       Date:  2012-01-31       Impact factor: 8.694

Review 3.  Body composition and skeletal health: too heavy? Too thin?

Authors:  Alexander Faje; Anne Klibanski
Journal:  Curr Osteoporos Rep       Date:  2012-09       Impact factor: 5.096

4.  Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.

Authors:  Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra
Journal:  Bone       Date:  2012-06-15       Impact factor: 4.398

Review 5.  Effects of hypogonadism on bone metabolism in female adolescents and young adults.

Authors:  Madhusmita Misra
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

6.  Skeletal outcomes by peripheral quantitative computed tomography and dual-energy X-ray absorptiometry in adolescent girls with anorexia nervosa.

Authors:  A D DiVasta; H A Feldman; J M O'Donnell; J Long; M B Leonard; C M Gordon
Journal:  Osteoporos Int       Date:  2016-07-08       Impact factor: 4.507

Review 7.  State of the art systematic review of bone disease in anorexia nervosa.

Authors:  Madhusmita Misra; Neville H Golden; Debra K Katzman
Journal:  Int J Eat Disord       Date:  2015-08-27       Impact factor: 4.861

8.  Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial.

Authors:  Madhusmita Misra; Debra K Katzman; Nara Mendes Estella; Kamryn T Eddy; Thomas Weigel; Mark A Goldstein; Karen K Miller; Anne Klibanski
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

9.  Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa.

Authors:  Alexander T Faje; Pouneh K Fazeli; Karen K Miller; Debra K Katzman; Seda Ebrahimi; Hang Lee; Nara Mendes; Deirdre Snelgrove; Erinne Meenaghan; Madhusmita Misra; Anne Klibanski
Journal:  Int J Eat Disord       Date:  2014-01-15       Impact factor: 4.861

Review 10.  Neuroendocrine consequences of anorexia nervosa in adolescents.

Authors:  Madhusmita Misra; Anne Klibanski
Journal:  Endocr Dev       Date:  2009-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.